Gastric intestinal metaplasia: when to treat? How to treat? : Current Opinion in Gastroenterology

Secondary Logo

Journal Logo

STOMACH AND DUODENUM: Edited by Tilak U. Shah

Gastric intestinal metaplasia: when to treat? How to treat?

Abdelfattah, Thaera,b; Shahab, Omera,b; Shah, Tilak U.a,b

Author Information
Current Opinion in Gastroenterology 37(6):p 602-608, November 2021. | DOI: 10.1097/MOG.0000000000000784


Purpose of review 

Gastric intestinal metaplasia (GIM) is an attractive target for surveillance and treatment as it can progress to gastric adenocarcinoma (GAC). Yet, GIM remains a challenging area for clinicians as most patients do not progress to cancer, and there are conflicting data regarding the benefits of surveillance and therapy. This review aims to summarize recently published GIM surveillance guidelines, to discuss, which patients with GIM may benefit from treatment, and to review pivotal and recent literature on GIM therapy.

Recent findings 

Guidelines published by American, British, and European gastroenterology societies do not recommend universal surveillance, but do suggest endoscopic surveillance in patients with risk factors for progression to GAC. Although light examination for at least 7 min and mapping biopsies may increase yield for dysplasia and GAC. In randomized trials, Helicobacter pylori eradication reduced risk of dysplasia and cancer. In GIM with visible dysplasia and early-stage GAC, endoscopic resection improves quality of life without reducing survival compared with surgery. Endoscopic ablation therapies have shown promise for invisible or extensive dysplasia.


Endoscopic resection is appropriate for visible dysplasia and early-stage GAC without high-risk features that persists despite H. pylori eradication therapy. Prospective studies are needed to assess the utility of endoscopic ablation in GIM.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid